ELOX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELOX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-17), Eloxx Pharmaceuticals's Beta is 2.91.
The historical data trend for Eloxx Pharmaceuticals's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eloxx Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jun13 | Jun14 | Jun15 | Jun16 | Jun17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Beta | Get a 7-Day Free Trial | 2.58 | 2.56 | 2.49 | 2.37 | 2.26 |
Eloxx Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Beta | Get a 7-Day Free Trial | 2.30 | 2.26 | 2.87 | 2.42 | 2.55 |
For the Biotechnology subindustry, Eloxx Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's Beta distribution charts can be found below:
* The bar in red indicates where Eloxx Pharmaceuticals's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Eloxx Pharmaceuticals (OTCPK:ELOX) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumit Aggarwal | director, officer: PRESIDENT AND CEO | 480 ARSENAL WAY, WATERTOWN MA 02472 |
Vijay Modur | officer: HEAD OF R&D | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451 |
Lindsay Androski | director | C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Gadi Veinrib | director | 12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101 |
Steven D Rubin | director | OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Jasbir Seehra | director | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451 |
Zafrira Avnur | director | 210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467 |
Alan Edmund Walts | director | 197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129 |
Daniel E. Geffken | officer: Chief Financial Officer | DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742 |
Pontifax Iv Gp L.p. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax Management 4 G.p. (2015) Ltd. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax (israel) Iv, L.p. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax (china) Iv L.p. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Pontifax (cayman) Iv L.p. | 10 percent owner | 4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Ran Nussbaum | director | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
From GuruFocus
By Marketwired • 07-10-2023
By Marketwired • 08-14-2023
By Marketwired • 08-03-2023
By sperokesalga sperokesalga • 05-24-2023
By GlobeNewswire GlobeNewswire • 11-10-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocusNews GuruFocusNews • 06-19-2022
By sperokesalga sperokesalga • 05-02-2023
By Stock market mentor Stock market mentor • 01-25-2023
By PurpleRose PurpleRose • 08-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.